Reference
1. Andersen AN, Gianaroli L, Felberbaum R, et al. Assisted reproductive technology in Europe, 2001. Results generated from European registers by ESHRE. Human reproduction (Oxford, England) 2005;20(5):1158-76.
2. Olivennes F, Belaisch-Allart J, Emperaire J-C, et al. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertility and sterility 2000;73(2):314-20.
3. Westergaard LG, Erb K, Laursen SB, et al. Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmic sperm injection: a prospective randomized study. Fertility and sterility 2001;76(3):543-9. doi: 10.1016/s0015-0282(01)01973-2 [published Online First: 2001/09/05]
4. Younis JS. ”Premature luteinization” in the era of GnRH analogue protocols: time to reconsider. Journal of assisted reproduction and genetics2011;28(8):689-92. doi: 10.1007/s10815-011-9585-x [published Online First: 2011/05/27]
5. Pelinck MJ, Hoek A, Simons AH, et al. Efficacy of natural cycle IVF: a review of the literature.Human reproduction update 2002;8(2):129-39. doi: 10.1093/humupd/8.2.129 [published Online First: 2002/07/09]
6. Smacklon N, Fauser BC. Regulation of follicle development and novel approaches to ovarian stimulation for IVF. Human reproduction update 2000;6(4):307-12. doi: 10.1093/humupd/6.4.307 [published Online First: 2000/09/06]
7. van Tilborg TC, Broekmans FJ. Individualized follicle-stimulating hormone dosing and in vitro fertilization outcome in agonist downregulated cycles: a systematic review. 2016;95(12):1333-44. doi: 10.1111/aogs.13032
8. Van Tilborg TC, Torrance HL, Oudshoorn SC, et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: The predicted poor responder.Human Reproduction 2017;32(12):2496-505.
9. Toftager M, Bogstad J, Bryndorf T, et al. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles. Human reproduction (Oxford, England)2016;31(6):1253-64. doi: 10.1093/humrep/dew051 [published Online First: 2016/04/10]
10. Kuang Y, Chen Q, Fu Y, et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization.Fertility and sterility 2015;104(1):62-70.e3. doi: 10.1016/j.fertnstert.2015.03.022 [published Online First: 2015/05/10]
11. Wang Y, Chen Q, Wang N, et al. Controlled ovarian stimulation using medroxyprogesterone acetate and hMG in patients with polycystic ovary syndrome treated for IVF: a double-blind randomized crossover clinical trial. Medicine2016;95(9)
12. Zhu X, Zhang X, Fu Y. Utrogestan as an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Medicine 2015;94(21):e909. doi: 10.1097/md.0000000000000909 [published Online First: 2015/05/29]
13. Zhu X, Ye H, Fu Y. The Utrogestan and hMG protocol in patients with polycystic ovarian syndrome undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments.Medicine 2016;95(28):e4193. doi: 10.1097/md.0000000000004193 [published Online First: 2016/07/20]
14. Zhu X, Ye H, Fu Y. Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a ”freeze all” strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg.Fertility and sterility 2017;107(2):379-86.e4. doi: 10.1016/j.fertnstert.2016.10.030 [published Online First: 2016/11/21]
15. Zhu X, Ye H, Fu Y. Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation. Fertility and sterility2017;108(3):505-12.e2. doi: 10.1016/j.fertnstert.2017.06.017 [published Online First: 2017/07/13]
16. Dong J, Wang Y, Chai WR, et al. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial.BJOG : an international journal of obstetrics and gynaecology2017;124(7):1048-55. doi: 10.1111/1471-0528.14622 [published Online First: 2017/03/10]
17. Yu S, Long H, Chang HY, et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Human reproduction (Oxford, England) 2018;33(2):229-37. doi: 10.1093/humrep/dex367 [published Online First: 2018/01/05]
18. Luke B, Brown MB, Wantman E, et al. Cumulative birth rates with linked assisted reproductive technology cycles. The New England journal of medicine 2012;366(26):2483-91. doi: 10.1056/NEJMoa1110238 [published Online First: 2012/06/29]
19. Maheshwari A, McLernon D, Bhattacharya S. Cumulative live birth rate: time for a consensus?Human reproduction (Oxford, England) 2015;30(12):2703-7. doi: 10.1093/humrep/dev263 [published Online First: 2015/10/16]
20. De Neubourg D, Bogaerts K, Blockeel C, et al. How do cumulative live birth rates and cumulative multiple live birth rates over complete courses of assisted reproductive technology treatment per woman compare among registries? Human reproduction (Oxford, England) 2016;31(1):93-9. doi: 10.1093/humrep/dev270 [published Online First: 2015/11/06]
21. McLernon DJ, Maheshwari A, Lee AJ, et al. Cumulative live birth rates after one or more complete cycles of IVF: a population-based study of linked cycle data from 178,898 women. Human reproduction (Oxford, England) 2016;31(3):572-81. doi: 10.1093/humrep/dev336 [published Online First: 2016/01/20]
22. SOULES MR, STEINER RA, CLIFTON DK, et al. Progesterone Modulation of Pulsatile Luteinizing Hormone Secretion in Normal Women*. The Journal of Clinical Endocrinology & Metabolism 1984;58(2):378-83. doi: 10.1210/jcem-58-2-378
23. Chabbert-Buffeta N, Skinner DC, Caraty A, et al. Neuroendocrine effects of progesterone. Steroids2000;65(10):613-20. doi:https://doi.org/10.1016/S0039-128X(00)00187-2
24. Xu B, Geerts D, Hu S, et al. The depot GnRH agonist protocol improves the live birth rate per fresh embryo transfer cycle, but not the cumulative live birth rate in normal responders: a randomized controlled trial and molecular mechanism study.Human Reproduction 2020;35(6):1306-18.
25. Lu X, Chen Q, Fu Y, et al. Elevated progesterone on the trigger day does not impair the outcome of Human Menotrophins Gonadotrophin and Medroxyprogesterone acetate treatment cycles. Scientific reports 2016;6:31112. doi: 10.1038/srep31112 [published Online First: 2016/08/09]
26. Siristatidis CS, Gibreel A, Basios G, et al. Gonadotrophin‐releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database of Systematic Reviews 2015(11)
27. Al‐Inany HG, Youssef MA, Ayeleke RO, et al. Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews2016(4)
28. Beguería R, García D, Vassena R, et al. Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Human Reproduction2019;34(5):872-80.
29. Roque M, Simon C. Time to pregnancy: as important for patients as underestimated by doctors.Fertility and sterility 2020;113(3):522-23.
30. Massin N. New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF. Human reproduction update 2017;23(2):211-20. doi: 10.1093/humupd/dmw047 [published Online First: 2017/01/08]
31. La Marca A, Capuzzo M. Use of progestins to inhibit spontaneous ovulation during ovarian stimulation: the beginning of a new era? Reproductive biomedicine online2019;39(2):321-31.
32. Alexandru P, Cekic SG, Yildiz S, et al. Progestins versus GnRH analogues for pituitary suppression during ovarian stimulation for assisted reproductive technology: a systematic review and meta-analysis. Reproductive biomedicine online2020;40(6):894-903.
33. Evans MB, Parikh T, DeCherney AH, et al. Evaluation of the cost-effectiveness of ovulation suppression with progestins compared with GnRH analogs in assisted reproduction cycles. Reproductive biomedicine online 2019;38(5):691-98.
34. Ata B, Seli E. A universal freeze all strategy: why it is not warranted. Current Opinion in Obstetrics and Gynecology 2017;29(3):136-45.
35. Ata B, Capuzzo M, Turkgeldi E, et al. Progestins for pituitary suppression during ovarian stimulation for ART: a comprehensive and systematic review including meta-analyses.Human reproduction update 2021;27(1):48-66.